[ad_1]
Pharmaceutical AstraZeneca, which works in conjunction with the University of Oxford, decided to interrupt a clinical trial to achieve a vaccine against COVID-19 because one of the participants, in the United Kingdom, suffers from “a potentially inexplicable disease,” reported Tuesday a company spokesperson to US media.
This vaccine candidate is in phase 3 of experimentation, which involves testing thousands of people to determine its effectiveness against SARS-CoV-2. In earlier stages it had produced “a good immune response.”
“Is is a routine action that happens whenever there is a potentially unexplained illness in one of the trials while it is being investigated, ensuring that the integrity of the studies is maintained, “the spokesperson told CNBC and the specialized outlet Stat.
Last month, Argentina and Mexico announced that they would be the countries in charge of producing this coronavirus vaccine for Latin America.
This is the first known case of a phase 3 trial that has been suspended. There are currently nine candidate vaccines at this stage.
The infectologist Carlos Álvarez states that it is a “usual decision in the face of a serious adverse event” and that once the severity analysis is carried out “it is decided to continue the same or with modifications or warnings. It can also be temporarily or permanently suspended ”.
[ad_2]
